利妥昔单抗对自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞的影响  

Influence of rituximab on Th1/Th2,Th3/Tr1 cells of patients with autoimmune hemolytic anemia

作　　者：陶书超[1] TAO Shuchao(Department of Blood Transfusion,Zaoyang First People's Hospital,Zaoyang,441299,China)

机构地区：[1]枣阳市第一人民医院输血科

出　　处：《临床血液学杂志（输血与检验）》2019年第5期801-804,共4页Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)

摘　　要：目的:探讨利妥昔单抗对自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞的影响。方法:以2017-06—2018-06收治的76例自身免疫性溶血性贫血患者为对象,按电脑数字表法随机分为2组,每组各38例,对照组予以常规治疗,试验组在常规治疗基础上予以利妥昔单抗治疗,对比2组疗效及外周血Th1/Th2、Th3/Tr1细胞情况。结果:治疗后,试验组Th1/Th2较对照组低,Th3/Tr1相关细胞(白细胞介素10、转化生长因子-β1)较对照组高,差异有统计学意义(P<0.05);治疗后,试验组血红蛋白较对照组高,网织红细胞、总胆红素较对照组低,差异有统计学意义(P<0.05);试验组总有效率(84.74%)较对照组(76.32%)高,差异有统计学意义(P<0.05)。结论:利妥昔单抗可有效改善自身免疫性溶血性贫血患者外周血Th1/Th2、Th3/Tr1细胞及相关血清学指标,进而提升临床疗效。Objective:To investigate the influence of rituximab on Th1/Th2,Th3/Tr1 cells of the patients with autoimmune hemolytic anemia. Method:A total of 76 patients with autoimmune hemolytic anemia were admitted to our hospital from June 2017 to June 2018 as the objects,according to the computer digital table method,these patients were randomly divided into two groups,each with 38 patients.The control group received routine treatment,and the experimental group received rituximab on the basis of conventional treatment.The efficacy and the peripheral blood Th1/Th2,Th3/Tr1 cells were compared between the two groups. Result:After treatment,the Th1/Th2 in the experimental group was lower than that in the control group,and the Th3/Tr1 related cells(including interleukin-10 and transforming growth factor-β1)were higher than those of the control group,with statistically significant(P<0.05).After treatment,the hemoglobin of the experimental group was higher than that of the control group,while the reticulocytes and total bilirubin were lower than those of the control group,with statistically significant(P<0.05).The total effective rate of the experimental group was 84.74%,which was higher than that of the control group(76.32%),with statistically significant(P<0.05).Conclusion:Rituximab can effectively improve Th1/Th2,Th3/Tr1 cells and related serological markers in peripheral blood of patients with autoimmune hemolytic anemia,and improve clinical efficacy.

关 键 词：利妥昔单抗 自身免疫性溶血性贫血 治疗 TH1/TH2 Th3/Tr1 

分 类 号：R556[医药卫生—血液循环系统疾病]